Ivonescimab Plus Chemotherapy Shows Consistent, Favorable Overall Survival Results in Western and Asian Patients in Updated Analysis from Global Phase III HARMONi Study
Go back to Ivonescimab Plus Chemotherapy Shows Consistent, Favorable Overall Survival Results in Western and Asian Patients in Updated Analysis from Global Phase III HARMONi Study| Stratcomm Media, Ltd. (NASDAQ: SMMT) | Delayed: 13.63 -1.35 (9.01%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $14.98 | 52 Week High | $19.75 | |||
| Open | $13.72 | 52 Week Low | $4.26 | |||
| Day High | $14.42 | P/E | N/A | |||
| Day Low | $13.20 | EPS | $0.00 | |||
| Volume | 5,696,042 | |||||
